Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya

Emerging Infectious Diseases

Volumn 6, Issue 6, 2000, Pages 585-594

  King, Charles H ^a,c   Muchiri, Eric M ^b   Ouma, John H ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MINISTRY OF HEALTH   (Kenya)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRIFONATE; PRAZIQUANTEL;

CHILD; DRUG EFFICACY; HUMAN; INFECTION RESISTANCE; KENYA; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NONHUMAN; PERSISTENT INFECTION; REINFECTION; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS;

EID: 0034489125     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0606.000606     Document Type: Review

References (53)

1. Drugs for parasitic infections
2. Emerging and reemerging helminthiases and the public health of China
3. Praziquantel
4. Drugs five years later: Praziquantel
5. Multicentre trials of praziquantel in human schistosomiasis: Design and techniques
6. Drug resistance to schistosomicides and other anthelmintics of medical significance
7. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: Ultrasonographic assessment
8. Predicting impact of school-based treatment for urinary schistosomiasis given by the Ghana Partnership for Child Development
9. The impact of a decade long opisthorchiasis control program in northeastern Thailand
10. Chemotherapy with praziquantel has the potential to reduce the prevalence of Echinococcus multilocularis in wild foxes (Vulpes vulpes)
11. Worming of dogs in mid-Wales for Echinococcus granulosus
12. Schistosomiasis japonica in the Philippines: The long-term impact of population-based chemotherapy on infection, transmission, and morbidity
13. An international initiative on praziquantel use
14. Praziquantel - Its use, cost and possible development of resistance
15. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal
16. Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low
17. Efficacy side effects of praziquantel in an epidemic focus of Schistosoma mansoni
18. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal
19. The development of resistance to anthelmintics: A perspective with an emphasis on the antischistosomal drug praziquantel
20. Schistosoma mansoni: Maturation rate and drug susceptibility of different geographic isolates
21. Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni
22. (Ca(2+)-Mg2+)ATPase in Schistosoma mansoni: Evidence for heterogeneity and resistance to praziquantel
23. Genetic analysis of hycanthone resistance in Schistosoma mansoni
24. Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection
25. Age-targeted chemotherapy for control of urinary schistosomiasis in endemic populations
26. Dynamics and control of Schistosoma haematobium transmission in Kenya: An overview of the Msambweni Project
27. Chemotherapy-based control of schistosomiasis haematobia. 3. Snail studies monitoring the effect of chemotherapy on transmission in the Msambweni area, Kenya
28. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel
29. Short report: Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni
30. Drug-resistant schistosomiasis: Resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific
31. Ultrasonographic assessment of urinary tract lesions due to Schistosoma haematobium in Niger after four consecutive years of treatment with praziquantel
32. Microbiology. When being hyper keeps you fit
33. Contingency loci, mutator alleles, and their interactions. Synergistic strategies for microbial evolution and adaptation in pathogenesis
34. Adaptive evolution of highly mutable loci in pathogenic bacteria
35. Chance favors the prepared genome
36. The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes
37. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium
38. Effect of praziquantel on hematuria and proteinuria in urinary schistosomiasis
39. Sensitivity and specificity of reagent strips in screening of Kenyan children for Schistosoma haematobium infection
40. Malumfashi Endemic Diseases Research Project, XV. The potential medical importance of bilharzia in northern Nigeria: A suggested rapid, cheap and effective solution for control of Schistosoma haematobium infection
41. Double-blind placebo controlled study of concurrent administration of albendazole and praziquantel in school children with schistosomiasis and geohelminths
42. Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya
43. Single dose metrifonate or praziquantel treatment in Kenyan children. II. Effects on growth in relation to Schistosoma haematobium and hookworm egg counts
44. The effect of different treatment regimens on the epidemiology of seasonally transmitted Schistosoma haematobium infections in four villages in the Senegal River Basin, Senegal
45. Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium
46. Schistosoma haematobium infection in Mauritania: Two years of follow-up after a targeted chemotherapy - A life-table approach of the risk of reinfection
47. Selective population chemotherapy among schoolchildren in Beheira governorate: The UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project
48. Resistance to reinfection after treatment of urinary schistosomiasis
49. Praziquantel: A new schistosomicide against Schistosoma haematobium